229 related articles for article (PubMed ID: 27460820)
1. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.
Nguyen L; Fifis T; Christophi C
BMC Cancer; 2016 Jul; 16():533. PubMed ID: 27460820
[TBL] [Abstract][Full Text] [Related]
2. Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.
Fifis T; Nguyen L; Malcontenti-Wilson C; Chan LS; Nunes Costa PL; Daruwalla J; Nikfarjam M; Muralidharan V; Waltham M; Thompson EW; Christophi C
Cancer Med; 2013 Oct; 2(5):595-610. PubMed ID: 24403226
[TBL] [Abstract][Full Text] [Related]
3. Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.
Nguyen L; Fifis T; Malcontenti-Wilson C; Chan LS; Costa PN; Nikfarjam M; Muralidharan V; Christophi C
BMC Cancer; 2012 Nov; 12():522. PubMed ID: 23153292
[TBL] [Abstract][Full Text] [Related]
4. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
[TBL] [Abstract][Full Text] [Related]
5. Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model.
Malcontenti-Wilson C; Chan L; Nikfarjam M; Muralidharan V; Christophi C
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e96-e104. PubMed ID: 17559382
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
7. Alterations in vascular architecture and permeability following OXi4503 treatment.
Chan LS; Malcontenti-Wilson C; Muralidharan V; Christophi C
Anticancer Drugs; 2008 Jan; 19(1):17-22. PubMed ID: 18043126
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
9. Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis.
Chan LS; Malcontenti-Wilson C; Muralidharan V; Christophi C
Anticancer Res; 2007; 27(4B):2317-23. PubMed ID: 17695520
[TBL] [Abstract][Full Text] [Related]
10. Leukemia regression by vascular disruption and antiangiogenic therapy.
Madlambayan GJ; Meacham AM; Hosaka K; Mir S; Jorgensen M; Scott EW; Siemann DW; Cogle CR
Blood; 2010 Sep; 116(9):1539-47. PubMed ID: 20472832
[TBL] [Abstract][Full Text] [Related]
11. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
Dalal S; Burchill SA
Eur J Cancer; 2009 Mar; 45(4):713-22. PubMed ID: 19136249
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
[TBL] [Abstract][Full Text] [Related]
16. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG
Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210
[TBL] [Abstract][Full Text] [Related]
17. Metastatic seeding of human colon cancer cell clusters expressing the hybrid epithelial/mesenchymal state.
Mizukoshi K; Okazawa Y; Haeno H; Koyama Y; Sulidan K; Komiyama H; Saeki H; Ohtsuji N; Ito Y; Kojima Y; Goto M; Habu S; Hino O; Sakamoto K; Orimo A
Int J Cancer; 2020 May; 146(9):2547-2562. PubMed ID: 31506938
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
Robert F; Sandler A; Schiller JH; Liu G; Harper K; Verkh L; Huang X; Ilagan J; Tye L; Chao R; Traynor AM
Cancer Chemother Pharmacol; 2010 Sep; 66(4):669-80. PubMed ID: 20043166
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
20. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Salmon HW; Siemann DW
Clin Cancer Res; 2006 Jul; 12(13):4090-4. PubMed ID: 16818709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
